Form 4: Fortress Biotech Increases Stake in Avenue Therapeutics Following Warrant Exercise

Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 33,724 shares of common stock as an equity fee following Avenue Therapeutics' receipt of proceeds from warrant exercises.

Summary

• Fortress Biotech, Inc., a reporting person and 10% owner of Avenue Therapeutics, Inc., has filed a Form 4 indicating a change in beneficial ownership.
• On March 31, 2025, Fortress Biotech acquired 33,724 shares of Avenue Therapeutics' common stock.
• This acquisition was due to an equity fee granted by Avenue Therapeutics to Fortress Biotech, equivalent to 2.5% of the gross amount of any debt or equity financing consummated by Avenue Therapeutics.
• The shares were granted following Avenue Therapeutics' receipt of proceeds from the exercise of previously issued warrants.
• Following the transaction, Fortress Biotech beneficially owns 328,524 shares of Avenue Therapeutics' common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction related to a pre-existing agreement. The increase in shareholding could be viewed slightly positively, but it's not a major event.

Positives

• Fortress Biotech increasing its stake in Avenue Therapeutics could be seen as a positive signal.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders. This filing indicates Fortress Biotech's increased investment in Avenue Therapeutics.

Related Party Transactions

• The equity fee granted to Fortress Biotech is a related party transaction.

Stakeholder Impact

• The increased stake of Fortress Biotech in Avenue Therapeutics may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Fortress Biotech, Avenue Therapeutics, Beneficial Ownership, Form 4, Equity Fee, Warrant Exercise, ATXI, Shares